$p_{I 2}$	Rate of CD8+ T cell activation induced by IL-2	2.4036	day⁻¹	[32]
$g_{I 2}$	Concentration of IL-2 necessary for half-maximal CD8+ T cell activation	$2.5036 \times 10^{3}$	IU L⁻¹	[32]
u	Rate of inhibition of surplus CD8+ T cells induced by Treg cells in the presence of IL-2	$2.3085 \times 10^{- 13}$	L² cell⁻² day⁻¹	[49]
$κ$	Concentration of IL-2 required to halve the immunosuppressive effect of Treg cells on CD8+ T cells	$2.5036 \times 10^{3}$	IU L⁻¹	[49]
j	Rate of activation of CD8+ T cells due to CD8+ T cell-lysed tumor cell debris	$1.245 \times 10^{- 4}$	day⁻¹	[32]
k	Tumor size required for half-maximal CD8+ T cell activation by CD8+ T cell-lysed tumor cell debris	$2.019 \times 10^{7}$	cells	[32]
$K_{L}$	Rate of CD8+ T cell depletion from chemotherapy toxicity	$4.524 \times 10^{- 1}$	day⁻¹	[32]
$δ_{L}$	Coefficient of chemotherapy toxicity on CD8+ T cells	$2 \times 10^{- 1}$	L mg⁻¹	[32]
$β$	Rate of circulating lymphocyte turnover	$6.3 \times 10^{- 3}$	day⁻¹	[32]
$α$	Rate of circulating lymphocyte production	$(3 \times 10^{9}) \cdot β$	cells L⁻¹ day⁻¹	[32]
$K_{C}$	Rate of lymphocyte depletion from chemotherapy toxicity	$5.7 \times 10^{- 1}$	day⁻¹	[32]
$δ_{C}$	Coefficient of chemotherapy toxicity on circulating lymphocytes	$2 \times 10^{- 1}$	L mg⁻¹	[32]
$μ_{I 2}$	Rate of excretion and elimination of IL-2	11.7427	day⁻¹	[32]
$ω$	Rate of IL-2 production from CD8+ T cells	$7.88 \times 10^{- 2}$	IU cell⁻¹day⁻¹	[32]
$ϕ$	Rate of IL-2 production from circulating CD4+ and naive CD8+ T cells	$1.788 \times 10^{- 7}$	IU cell⁻¹day⁻¹	[32]
$ζ$	Concentration of IL-2 for half-maximal CD8+ T cell IL-2 production	$2.5036 \times 10^{3}$	IU L⁻¹	[32]
$γ_{1}$	The rate of excretion and elimination of irinotecan	$4.077 \times 10^{- 1}$	day⁻¹	[32]
$η$	Rate of cetuximab and panitumumab turnover and excretion	$1.386 \times 10^{- 1}$ for cetuximab $9.242 \times 10^{- 2}$ for panitumumab	day⁻¹	[32]